Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Urology Oncology|August 4, 2019
Defining Risk Categories for a Significant Decline in Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy: Implications for Patient Follow-upAlberto Martini, Ugo Giovanni Falagario, Shivaram Cumarasamy, et al.
European Urology|September 19, 2018
A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial NephrectomyAlberto Martini, Shivaram Cumarasamy, Alp Tuna Beksac, et al.
European Urology Oncology|March 23, 2024
Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical CystectomyReuben Ben-David, Neeraja Tillu, Shivaram Cumarasamy, et al.
BJU International|March 3, 2019
A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcomeAlberto Martini, Joanna Wang, Nicholas M Brown, et al.
Urology|February 14, 2019
Downgrading of Grade Group After Radical Prostatectomy: Comparison of Multiparametric Magnetic Resonance Imaging Guided Fusion Biopsy and Standard 12-Core BiopsyAlp Tuna Beksac, Stanislaw Sobotka, Paige Xu, et al.
Urologic Oncology|September 14, 2024
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysisReuben Ben-David, Sarah Lidagoster, Jack Geduldig, et al.
The Journal of Urology|February 8, 2019
Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic TestsUgo G Falagario, Alp Tuna Beksac, Alberto Martini, et al.
The Journal of Urology|December 20, 2018
Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic LevelAlp Tuna Beksac, Shivaram Cumarasamy, Ugo Falagario, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
Pageof 2